Clinical Commissioning Policy Statement: Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naïve metastatic prostate cancer

Document first published:: 22 January 2016
Page updated:: 15 November 2017
Topic:: Cancer, Commissioning
Publication type:: Policy or strategy

NHS England will routinely commission this specialised treatment in accordance with the criteria described in this policy.

Document

Clinical Commissioning Policy Statement: Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naïve metastatic prostate cancer

Clinical Commissioning Policy Statement: Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naïve metastatic prostate cancer

PDF
460 KB
13 pages